This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient ...

FDA approves Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

A study identifies three patient subgroups in large B-cell lymphoma, revealing distinct responses to CD19 CAR T cell therapy ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

The CAR-T Cell Therapy Market is growing rapidly with expanding indications, rising trials, and innovations in solid tumor and autoimmune applications.